Pfizer has introduced the firm’s Nivestym (filgrastim-aafi) biosimilar in the US, at the previously-promised “significant discount” to the current wholesale acquisition cost (WAC) of Amgen’s Neupogen original, and a double-digit reduction on the price of competing biosimilar and follow-on products.
Revealing that shipments to wholesalers had begun on 24 September, Pfizer announced that the biosimilar had been available since 1...



